Jun Ma

Jun Ma

Auto-generated profile, based on publicly available information

Jun Ma

College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, PR China; Heilongjiang Provincial Key Laboratory of Pathogenic Mechanism for Animal Disease and Comparative Medicine, Harbin 150030, PR China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2024 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
JJJunze Jiang
Junze Jiang
XZXintong Zhou
Xintong Zhou
HCHao Chen
Hao Chen
XWXin Wang
Xin Wang
YRYongbao Ruan
Yongbao Ruan
JMJun Ma
Jun Ma

23 February 2022 in Life Sciences
Verified
Journal Article
Closed access
HCHao Chen
Hao Chen
TNTong Nie
Tong Nie
PZPenglu Zhang
Penglu Zhang
JMJun Ma
Jun Ma
ASAnshan Shan
Anshan Shan

1 April 2021 in Preventive Veterinary Medicine
Verified
Journal Article
Closed access
HGHongyan Gao
Hongyan Gao
JMJun Ma
Jun Ma

19 March 2024 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
JJJunze Jiang
Junze Jiang
YRYongbao Ruan
Yongbao Ruan
XLXiaohui Liu
Xiaohui Liu
JMJun Ma
Jun Ma
HCHao Chen
Hao Chen

22 February 2024 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
HCHao Chen
Hao Chen
WXWang Xin
Wang Xin
JJJunze Jiang
Junze Jiang
ASAnshan Shan
Anshan Shan
JMJun Ma
Jun Ma

1 December 2023 in Food & Function
Verified
Journal Article
Closed access
PDF file
TNTong Nie
Tong Nie
XWXin Wang
Xin Wang
ALAqun Li
Aqun Li
ASAnshan Shan
Anshan Shan
JMJun Ma
Jun Ma
Reducing fat deposits in hepatocytes is a direct treatment for nonalcoholic fatty liver disease (NAFLD) and the fatty acid metabolic processes mediated by fatty acid β-oxidation are important for the prevention of NAFLD. In this study, we established high-fat-diet models in vitro and in vivo to investigate the mechanism by which hesperidin (HDN) prevents NAFLD by modulating fatty acid β oxidation. Based on LC-MS screening of differential metabolites, many metabolites involved in phospholipid and lipid metabolism were found to be significantly altered and closely associated with fatty acid β-oxidation. The results from COIP experiments indicated that HDN increased the deacetylation of PGC1α by SIRT1. In addition, the results of CETSA and molecular docking experiments suggest that HDN targeting of SIRT1 plays an important role in their stable binding. Meanwhile, it was found that HDN reduced fatty acid uptake and synthesis and promoted the expression of SIRT1/PGC1α and fatty acid β-oxidation, and the latter process was inhibited after transfection to knockdown SIRT1. The results suggest that HDN improves NAFLD by promoting fatty acid β-oxidation through activating SIRT1/PGC1α. Thus, the findings indicate that HDN may be a potential drug for the treatment of NAFLD.